Fmr LLC Passage Bio, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Fmr LLC holds 21,054 shares of PASG stock, worth $13,685. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,054

Previous 21,070 0.08%

Holding current value

$13,685

Previous $28,000 42.86%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$0.79 - $1.58 $12 - $25	-16 Reduced 0.08%	21,054 $16,000
Q1 2024 May 13, 2024	SELL	$0.86 - $1.73 $35,217 - $70,845	-40,951 Reduced 66.03%	21,070 $28,000
Q2 2023 Aug 11, 2023	BUY	$0.82 - $1.19 $1,148 - $1,666	1,400 Added 2.31%	62,021 $58,000
Q1 2023 May 11, 2023	BUY	$0.96 - $1.88 $932 - $1,825	971 Added 1.63%	60,621 $58,000
Q4 2022 Feb 13, 2023	SELL	$1.06 - $1.48 $1,060 - $1,480	-1,000 Reduced 1.65%	59,650 $82,000
Q3 2022 Nov 10, 2022	SELL	$1.22 - $2.48 $131 - $267	-108 Reduced 0.18%	60,650 $76,000
Q2 2022 Aug 12, 2022	SELL	$1.63 - $3.46 $517,365 - $1.1 Million	-317,402 Reduced 83.93%	60,758 $143,000
Q1 2022 May 13, 2022	SELL	$2.66 - $6.49 $3.76 Million - $9.18 Million	-1,413,884 Reduced 78.9%	378,160 $1.17 Million
Q4 2021 Feb 14, 2022	SELL	$6.24 - $10.2 $24 Million - $39.2 Million	-3,840,512 Reduced 68.18%	1,792,044 $11.4 Million
Q3 2021 Nov 15, 2021	SELL	$9.73 - $15.52 $9.06 Million - $14.4 Million	-930,752 Reduced 14.18%	5,632,556 $56.1 Million
Q2 2021 Aug 13, 2021	BUY	$12.44 - $19.45 $81.6 Million - $128 Million	6,563,308 New	6,563,308 $86.9 Million

Others Institutions Holding PASG

# of Institutions

Shares Held

32.2M

Call Options Held

8.3K

Put Options Held

400

View Full List

About Passage BIO, Inc.

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.4M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

More about PASG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account